Randomized controlled trials in health technology assessment: overkill or overdue?

@article{Bentzen2008RandomizedCT,
  title={Randomized controlled trials in health technology assessment: overkill or overdue?},
  author={S\oren M\oller Bentzen},
  journal={Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  year={2008},
  volume={86 2},
  pages={142-7}
}
Evidence-based medicine has become a cornerstone in the development of radiation oncology and the randomized controlled phase III trial remains the gold standard for assessing differential benefits in clinical outcome between therapies. Health technologies aimed at improving treatment quality should primarily be tested using process measures or operational characteristics, the reason being that the sensitivity and specificity of clinical outcome is low for detecting quality improvements. The… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.

International journal of radiation oncology, biology, physics • 2011
View 7 Excerpts
Highly Influenced

Proton therapy - a reality in Norway from 2023.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke • 2018

Improving radiotherapy through medical physics developments.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2015

Similar Papers

Loading similar papers…